Uppsala University Hospital / Uppsala University
Uppsala University Hospital is Sweden's oldest; its neuroendocrine tumour centre built by Kjell Öberg is an ENETS Centre of Excellence with long experience of somatostatin analogues and radionuclide therapy, and Sweden's national Skandion proton clinic opened next door in 2015.
Overview
Akademiska sjukhuset and Uppsala University form one of Scandinavia's leading cancer research environments. Uppsala's neuroendocrine tumour centre, built by Kjell Öberg, is an ENETS Centre of Excellence with long experience of somatostatin analogues and peptide receptor radionuclide therapy, and Bengt Glimelius's group shaped Nordic rectal cancer radiotherapy trials. The Skandion Clinic, Sweden's national proton therapy facility co-owned by the university regions, opened in Uppsala in 2015 using IBA equipment. Tobias Sjöblom's laboratory contributed to the first colorectal cancer exome sequencing and runs the U-CAN biobank, Uppsala scientists founded Olink Proteomics, and the Uppsala Clinical Research Center supports national trials.
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-22.
Matched to Uppsala University Hospital, including child institutions. 177 works · 1,457 citations · 81% open access · 18% clinical trials · 1% reviews.
- Gustav Jörgen Ullenhag45 works
- Roger Olofsson Bagge22 works
- Lars Ny20 works
- Hildur Helgadóttir19 works
- Antonios Valachis14 works
- Aglaia Schiza13 works
- Ana Carneiro12 works
- Viktoria Ekström-Rydén12 works
- Joakim Folkesson11 works
- Bengt L. G. Glimelius11 works
- Neuroendocrine tumour centre
- Skandion proton clinic
- Gastrointestinal radiotherapy trials
- U-CAN biobank
- Proteomics
Similar pages
not linked directly; found by shared links- InstitutionErasmus MC Cancer Institute
Shares Glioma & glioblastoma, Somatostatin receptor 2, Lutetium-177 dotatate, Neuroendocrine tumours.
- InstitutionWest German Cancer Center (WTZ), University Hospital Essen
Shares IBA (Ion Beam Applications), Lutetium-177 dotatate, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- InstitutionInselspital, Bern University Hospital / University Cancer Center Inselspital
Shares Glioma & glioblastoma, Somatostatin receptor 2, Lutetium-177 dotatate, Neuroendocrine tumours.
- PersonSimron Singh
Shares Somatostatin receptor 2, Lutetium-177 dotatate, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- PersonEmily K. Bergsland
Shares Somatostatin receptor 2, Lutetium-177 dotatate, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- InstitutionOslo University Hospital, The Norwegian Radium Hospital
Shares Karolinska University Hospital, Radioligand therapy (beta emitters), Prostate cancer.
- InstitutionSahlgrenska University Hospital / Sahlgrenska Center for Cancer Research
Shares Karolinska University Hospital, Radioligand therapy (beta emitters).
- CompanyPOINT Biopharma
Shares Somatostatin receptor 2, Neuroendocrine tumours, Radioligand therapy (beta emitters), Prostate cancer.